Inducement

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 3, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Inducement, Compensated emancipation, Therapy, Employment

The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan.

Key Points: 
  • The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan.
  • The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date.
  • The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to each employee’s continued employment with Viridian through the applicable vesting dates.

CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, April 19, 2024
Managed Care, General Health, Health, Practice Management, Transplant, Medicine, Compensation, Patient, Employment, Caregiver, Inducement

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock (the “Inducement Option”) and 487,804 restricted stock units (the “Inducement RSUs” ) to John Hanna, CareDx’s newly appointed President and Chief Executive Officer.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock (the “Inducement Option”) and 487,804 restricted stock units (the “Inducement RSUs” ) to John Hanna, CareDx’s newly appointed President and Chief Executive Officer.
  • The Inducement Option and the Inducement RSUs were approved by the Compensation and Human Capital Committee of CareDx’s board of directors on March 25, 2024, and were an inducement material to Mr. Hanna’s employment with CareDx in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Option has an exercise price of $8.20 and will vest over four years, with 25% of the total number of shares subject to the Inducement Option vesting on April 15, 2025, the one-year anniversary of the date of commencement of Hanna’s employment with CareDx, and 1/48th of the total number of shares subject to the Inducement Option vesting at the end of each calendar month thereafter, subject in each case to Hanna’s continued services with CareDx on each vesting date.
  • The Inducement RSUs will vest in four equal, annual installments beginning on April 15, 2025, the one-year anniversary of the date of commencement of Hanna’s employment with CareDx, subject in each case to Hanna’s continued services with CareDx on each vesting date.

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, April 11, 2024
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Inducement, Compensated emancipation, Employment

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units (“RSUs”) to twelve newly hired employees with a grant date of April 9, 2024 (the “Inducement Grants”).

Key Points: 
  • bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units (“RSUs”) to twelve newly hired employees with a grant date of April 9, 2024 (the “Inducement Grants”).
  • The Inducement Grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2021 Inducement Plan.
  • The RSUs approved under the Inducement Grants vest equally over four years, with 25% vesting each year on the anniversary of the vesting date.
  • The Company granted the RSUs as inducement materials to each individual entering into employment with bluebird bio, Inc. in accordance with NASDAQ Listing Rule 5635(c)(4).

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, April 5, 2024
Inducement, SAN, Employment, Compensated emancipation, Liver

The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”).

Key Points: 
  • The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”).
  • The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date.
  • The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to each employee’s continued employment with 89bio through the applicable vesting dates.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, April 4, 2024
Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Inducement, Employment, Compensated emancipation, Therapy

The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan.

Key Points: 
  • The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan.
  • The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date.
  • The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to each employee’s continued employment with Viridian through the applicable vesting dates.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Inducement, Compensated emancipation, Therapy, Employment

The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan.

Key Points: 
  • The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan.
  • The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date.
  • The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to each employee’s continued employment with Viridian through the applicable vesting dates.

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 6, 2024
Oncology, Professional Services, Health, Data Analytics, Technology, Software, Biotechnology, Inducement, RSU, Compensated emancipation, Employment, Helmy Eltoukhy

The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a RSU award agreement covering the grant.
  • The stock options are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option award agreement covering the grant.

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, February 5, 2024
SAN, Employment, Liver, Compensated emancipation, Inducement

The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”).

Key Points: 
  • The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”).
  • The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date.
  • The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to each employee’s continued employment with 89bio through the applicable vesting dates.

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, December 19, 2023
Liver, Inducement, Compensated emancipation, Employment, SAN

The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”).

Key Points: 
  • The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”).
  • The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date.
  • The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to each employee’s continued employment with 89bio through the applicable vesting dates.

IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, December 11, 2023
Immunotherapy, Public, Ovarian cancer, Drug development, CMO, Roche, Statistics, Therapy, Novartis, Inducement, GSK, PARP, Calendar, Bicycle, Genentech, Internal medicine, Compensated emancipation, Public health, Employment, Epidemiology, Pharmaceutical industry

LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics. He will report to IMUNON’s President and Chief Executive Officer, Dr. Corinne Le Goff.

Key Points: 
  • Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics.
  • He will report to IMUNON’s President and Chief Executive Officer, Dr. Corinne Le Goff.
  • Each of the Inducement Option and the Restricted Inducement Grant is an inducement material to Dr.
  • Hazard entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).